Sanofi's diabetes drug Adlyxin (lixisenatide) could benefit Parkinson's patients

Parkinson’s patients who took Sanofi pharma’s diabetes drug Adlyxin (lixisenatide) were found to be “significantly better off in their movements” after a one-year trial

’ The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner, his Bordeaux University Hospital counterpart.

“If our pilot data are confirmed, it is going to dramatically change the quality of life of the patients,” said Rascol.

Parkinson’s is a brain disorder that affects an estimated 10mn people worldwide and leads to symptoms including body tremors, slow movement and — in severe cases — dementia.’

1 Like